[1] Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology,2009,136（1）:65-80.
[2] Backhed F,Ding H,Wang T,et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA,2004,101（44）:15718-15723.
[3] Backhed F,Manchester JK,Semenkovich CF,et al. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA,2007,104（3）:979-984.
[4] Ley RE,Bankhed F,Turnbaugh P,et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA,2005,102（31）:11070-11075.
[5] Ley RE,Turnbaugh PJ,Klein S,et al. Microbial ecology: human gut microbes associated with obesity. Nature,2006,444（7122）: 1022-1023.
[6] Kalliomaki M,Collado MC,Salminen S,et al. Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr,2008,87（3）:534-538.
[7] Bugianesi E,Moscatiello S,Ciaravella MF,et al. Insulin resistance in nonalcoholic fatty liver disease. CurrPharm Des,2010,16（17）:1941-1951.
[8] Farrell GC. Signalling links in the liver:knitting SOCS with fat and inflammation. J Hepatol,2005,43（1）:193-196.
[9] Cani PD,Amar J,Iqiesias MA,et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes,2007,56（7）: 1761-1772.
[10] Rabot S,Membrez M,Bruneau A,et al. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. FASEB J,2010,24（12）:4948-4959.
[11] Vijay-kumar M,Aitken JD,Carvalho FA,et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science,2010,328（5975）:228-231.
[12] Delzenne NM,Cani PD. Gut microbiota and the pathogenesis of insulin resistance. Curr Diabetes Rep,2011,11（3）:154-159.
[13] Larsen N,Vogensen FK,van den Berg FW,et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One,2010,5（2）:e9085.
[14] Cani PD,Bibiloni R,Knauf C,et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes,2008,57（6）:1470-1481.
[15] Shanab AA,Scully P,Crosbie O,et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with Toll-like receptor 4 expression and plasma levels of interleukin 8. Digest Dis Sc,2011,56（5）: 1524-1534.
[16] Sajjad A,Mottershead M,Syn WK,et al. Ciprofloxacin suppresses bacterial overgrowth,increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis. Aliment PharmTherap,2005,22（4）:291-299.
[17] Fan JG,Xu AJ,and Wang GL. Effect of lactulose on establishment of a rat non-alcoholic steatohepatitis model. World J Gastroentero,2005,11（32）:5053-5056.
[18] Wu WC,Zhao W,and Li S. Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats. World J Gastroentero,2008,14（2）: 313-317.
[19] Corrodi,P. Jejunoileal bypass:change in the flora of the small intestine and its clinical impact. Rev Infect Dis,1984,6（Suppl.1）,S80-S84.
[20] Abu-shanab A,Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastro Hepat,2010,7（12）: 691-701.
[21] Yalniz M,Bahcecioqlu IH,Ataseven H,et al. Serum adipokine and ghrelin levers in nonalcoholic steatohepatitis. Mediators Inflamm. 2006,2006（6）:34295.
[22] Harte AL,da Silva NF,Creely SJ,et al. Research elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm,2010,7:15.
[23] Verdam FJ,Rensen SS,Driessen A,et al. Novel evidence for chronic exposure to endotoxin in human nonalcoholic steatohepatitis. J Clin Gastroenterol,2011,45（2）:149-152.
[24] Amar J,Burcelin R,Ruidavets JB,et al. Energy intake is associated with endotoxemia in apparently healthy men. Ame J Clin Nutrition,2008,87（5）:1219-1223.
[25] Huang W,Metlakunta A,Dedousis N,et al. Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. Diabetes,2010,59（2）:347-357.[26] Guerra Ruiz A,Casafont F,Crespo J,et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients:evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes surg,2007,17（10）:1374-1380.
[27] Iacono A,Raso GM,Canani RB,et al. Probiotics as an emerging therapeutic strategy to treat NAFLD:focus on molecular and biochemical mechanisms. J Nutr Biochem,2011,22（8）:699-711.[28] Li L,Chen L,Hu L,et al. Nuclear factor high-mobility group box1 mediating the activation of toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology,2011,54（5）:1620-1630.
[29] Rivera CA,Adegboyega P,van Rooijen N,et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol,2007,47（4）: 571-579.
[30] Ttuy S,Ladurnerr R,Volynets V,et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr,2008,138（8）:1452-1455.
[31] Markell T A,Crisostomo PR,Wairiuko GM,et al. Cytokines in necrotizing enterocolitis. Shock,2006,25（4）:329-337.
[32] Dumas ME,Barton RH,Toye A,et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci USA,2006,103（33）:12511-12516.
[33] Miele L,Valenza V,La Torre G,et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology,2009,49（6）:1877-1887.
[34] Cesaro C,Tiso A,Del Prete A,et al. Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis,2010,43（6）:431-438.
[35] Iacono A,Raso GM,Canasi RB,et al. Probiotics as an emeging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem,2011,22（8）:699-711. |
